Cui Dongshu, Chenglian Branch: The head car companies that grew in the auto market this year showed stronger characteristics of their own brands. Cui Dongshu, secretary general of Chenglian Branch, issued a document saying that the national new energy passenger car market showed a continuous upward trend in 2024, with a penetration rate of 52% for the retail sales of 1.26 million vehicles in November. With the strong growth of the extension program at the beginning of the year, the scrapping and renewal and trade-in since August have promoted the explosive growth of the entry-level hybrid of economical electric vehicles, forming a good performance that new energy vehicles will become stronger and stronger in 2024. This year, the head car companies that have grown in the auto market are characterized by stronger independent brands. In particular, the new energy trend of traditional independent car companies has surpassed the new forces, and more and more students have become "three excellent students" with mixed, pure electric and all-round development.Huichuan Technology traded 2.46 million shares today, with a turnover of 151 million yuan. Huichuan Technology traded 2.46 million shares today, with a turnover of 151 million yuan, accounting for 10.48% of the total turnover of the day. The transaction price was 61.25 yuan, which was the same as the market closing price of 61.25 yuan.Guotai Junan: The long-term incremental "option" brought by humanoid robots is expected to help the valuation of the rare earth sector rise. When looking forward to the strategy of the rare earth sector in 2025, Guotai Junan said that the market had expected that with the slowdown in the growth of core demand power such as new energy vehicles and wind power in the future, the demand for rare earth markets is under downward pressure. However, we expect that the rising consumption of magnetic materials for new energy vehicles and the warming demand for wind power are still expected to support the basic demand growth, and the demand for equipment renewal that began to land in 2024 is expected to become a new driving force for rare earth demand. On the supply side, an orderly pattern of domestic supply has been established, with many overseas planning increments but slow actual volume, and continuous supply-side constraints. In addition, the long-term incremental "options" brought by humanoid robots are also expected to help the valuation of the plate rise.
Jianfan Bio: The plasma separator was certified by the European Union MDR, and Jianfan Bio announced that Jianfan Blood Purification Company, a wholly-owned subsidiary, recently received a notice from the EU announcement agency that its plasma separator was certified by the European Union MDR in accordance with the EU Medical Devices Regulation 2017/745, and can be sold in EU countries and other countries that recognize the EU CE certification.Nanxin Technology: The equity of shareholders Shunwei Technology and its concerted actions changed to less than 5%. Nanxin Technology announced that the shareholders of the company Shunwei Technology and its concerted actions Hangzhou Shunying, Wuhan Shunying and Wuhan Shunhong reduced their holdings of the company's shares and passively diluted their equity, and the total number of shares held by the company changed from 30,843,800 shares to 21,272,800 shares, accounting for 7.2826% to 4.9999% of the company's total share capital, no longer.There are more than 100 suppliers who need to pay for the goods. On December 12, after learning that the capital chain of Jiyue Automobile was broken, many suppliers from all over the country came to Jiyue Automobile Headquarters Building and asked Jiyue Automobile to pay for the goods. The reporter learned that there are more than 100 employees in the supplier group established at the site. These suppliers undertake many businesses, including equipment, fine products, insurance, electronics, batteries, etc., and the maximum payment required by the company is up to 100 million yuan. Most suppliers owe between 1 million yuan and 10 million yuan. Among them, the total amount of arrears registered by 19 suppliers in the group is nearly 96 million yuan, and the average balance of arrears of each supplier exceeds 5 million yuan. (CBN)
Dong Yuhui has recently established three new companies. According to Tianyancha App, Zisan Province (Beijing) Technology Co., Ltd. was recently established, with the legal representative of Dong Yuhui and the registered capital of 10 million RMB. Its business scope includes Internet information services, value-added telecommunications services of the first kind, network culture management, film screening, alcohol management, radio and television program production and management, etc. According to the shareholder information, the company is jointly held by Zhongnan Yuantiao (Xi 'an) Technology Co., Ltd., Dong Yuhui and Long song Youhe (Beijing) Technology Partnership (Limited Partnership). It is worth mentioning that Zhongnan Yuantiao (Xi 'an) Technology Co., Ltd. and Long song Youhe (Beijing) Technology Partnership (Limited Partnership) were established recently with registered capital of 10 million RMB and 1 million RMB respectively.US President-elect Trump: Opposing Ukrainian armed forces to attack Russia with US long-range missiles has further escalated the conflict.CITIC Securities: The resonance between supply and demand of medical beauty accelerates the space expansion, and the difference in operating ability promotes the evolution of the industry structure. CITIC Securities Research Report stated that the medical beauty industry has both medical and consumption attributes, and the medical attribute has strong product-driven characteristics, while the consumption attribute has high operating ability requirements. The medical beauty botulinum toxin track is also affected by the dual attributes of medicine and consumption: 1) The increase in penetration rate, the acceleration of compliance substitution and the extension of indications have brought about high demand for medical beauty botulinum toxin, and with the recent supply expansion, the industry scale has experienced high growth; 2) The iteration of product innovation is slow, brand barriers are created through marketing, doctors are empowered through direct sales, and control is strengthened to enhance product competitiveness. Recently, a variety of medical botulinum toxins in China have been approved, and the promotion of low-priced products is expected to push up the penetration rate, and enterprises with strong operational capabilities will enter the market or promote the evolution of the pattern.
Strategy guide 12-14
Strategy guide
12-14
Strategy guide
Strategy guide
12-14